Phospha 250 Neutral Tablet
NDC Package 64980-729-01
Package Information
Phospha 250 Neutral (dibasic sodium phosphate, monobasic potassium phosphate and monobasic sodium phosphate) tablets is this drug may be used in people who cannot get enough phosphorus from their diets. This formulation utilizes a tablet delivery system. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 64980-729.
Identification & Billing
- RxCUI: 200251 - sodium phosphate, dibasic 852 MG / potassium phosphate, monobasic 155 MG / sodium phosphate, monobasic 130 MG Oral Tablet
- RxCUI: 200251 - potassium phosphate 155 MG / sodium phosphate, dibasic 852 MG / sodium phosphate, monobasic 130 MG Oral Tablet
- RxCUI: 200251 - K+ phosphate 155 MG / Sodium Phosphate, Dibasic 852 MG / Sodium Phosphate, Monobasic 130 MG Oral Tablet
- RxCUI: 200251 - Pot phosphate 155 MG / Sodium Phosphate, Dibasic 852 MG / Sodium Phosphate, Monobasic 130 MG Oral Tablet
- RxCUI: 656742 - Phospha 250 Neutral 852 MG / 155 MG / 130 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 64980 - Rising Pharma Holdings, Inc.
- 64980-729 - Phospha 250 Neutral
- 64980-729-01 - 100 TABLET in 1 BOTTLE
- 64980-729 - Phospha 250 Neutral
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 64980-729-01 identifies a specific commercial package of 100 tablet in 1 bottle of Phospha 250 Neutral, a human prescription drug labeled by Rising Pharma Holdings, Inc.. This tablet is formulated for oral use and contains potassium phosphate, monobasic; sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rising Pharma Holdings, Inc. on March 28, 2026. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This drug may be used in people who cannot get enough phosphorus from their diets. Phosphorus is a natural body mineral that is very important for building and maintaining bone. It helps control the amount of calcium in the body and urine.
How is this Rising Pharma Holdings, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 64980072901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.